Skip to main content

Table 3 Twelve months outcomes after cART initiation according to treatments that did/did not follow the guidelines

From: The effect of adherence to guidelines for initial antiretroviral therapy on 1-year outcomes: a French cohort study

 

All population

"when-to-start" guidelines

"what-to-start" guidelines

Characteristic

N = 1,365

Followed guidelines (n = 1,214)

Outside of guidelines (n = 151)

P

Followed guidelines (n = 1,215)

Outside of guidelines (n = 150)

P

cART modification (%)

43.6

43.7

43.4

-

41.2

62.7

<0.001

12 months CD4 (/mm3) (median [IQR])

395

369

619

<0.001

406

313

<0.001

[241-538]

[224-506]

[504-766]

[257-548]

[148-484]

CD4 gain (/mm3) (median [IQR])

137

139

89

0.006

144

69

<0.001

[33-238]

[39-239]

[0-216]

[40-239]

[0-204]

12 months HIV-RNA (log copies/mL) (median [IQR])

1.7

1.7

1.7

-

1.7

1.9

<0.001

[1.6-2.3]

[1.6-2.3]

[1.7-2.4]

[1.6-2.2]

[1.7-3.4]

HIV-RNA <50 copies/mL (%)

64.6

64.3

66.9

-

66.8

47.3

<0.001

Deceased (%)

0.8

0.9

0

-

0.6

2.7

0.007

  1. Abbreviations: IQR interquartile range, cART combined antiretroviral therapy, HIV human immunodeficiency virus.